Evidence map›Paper›PMID 41025432›Full record

ArticleThe Cochrane database of systematic reviews2025

Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity.

Huai Leng Pisaniello, Samuel L Whittle, Renea V Johnston, Vanessa Glennon, Liesl Grobler, Sheila Cyril, Anneliese D Arno, Rachelle Buchbinder

Abstract read
In one paragraph

Article in The Cochrane database of systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Subcutaneous immunotherapy as a catalyst for decentralized, oncologist-led cancer care: a mixed-methods analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huai Leng PisanielloSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.ORCID 0000-0002-0425-1697
Samuel L WhittleSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Renea V JohnstonSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Vanessa GlennonSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Liesl GroblerSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Sheila CyrilSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Anneliese D ArnoSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Rachelle BuchbinderSchool of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To investigate the benefits and harms of dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in adults with rheumatoid arthritis or psoriatic arthritis, who have been in sustained remission or low disease activity. This is a common review protocol, outlining the approach for two separate Cochrane reviews for people with rheumatoid arthritis or psoriatic arthritis. Dose reduction or discontinuation of csDMARDs in adults with rheumatoid arthritis, who have been in sustained remission or low disease activity Dose reduction or discontinuation of csDMARDs in adults with psoriatic arthritis, who have been in sustained remission or low disease activity.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidAdultHumansRandomized Controlled Trials as TopicRemission InductionAntirheumatic Agents

Identifiers

PMID41025432
PMCPMC12481666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.